Posted 23 Feb. 2023 at 07:17 PMUpdated Feb 23. 2023 at 07:28 PM
The biotech sector, which had found itself in the spotlight during the health crisis, suffered a severe setback in 2022.
In the United States, the S&P Biotech fell 27% in an environment hostile to technology stocks. After the successes of Moderna and BioNTech, which provided the world with messenger RNA vaccines against Covid in record time, the euphoria has subsided. These two biotech stars, still unknown three years ago, have seen their stock prices halve from the peaks of August 2021, but they still post impressive valuations of, respectively, 58 billion and 32 billion. dollars.
Related posts:
Home delivery of medicines is gaining ground
Motor Expo 5 days, reservations exceed 15,000 cars, "EV" star
5 Big Things to Know in Financial Markets This Week: The Fed’s Favorite Inflation Data Is Coming Pro...
Beware of Scams: Meta's Threads Social Network Under Attack by Fraudulent Apps
Session: Private individuals must be able to sell their surplus electricity
Visa Africa Fintech Accelerator Program: Supporting African Startups and Entrepreneurs in Fintech
"Elon Musk's Battle Against Government-Funded Media on Twitter"
Crude oil futures fell during the Asian session